ID   FMO2_HUMAN              Reviewed;         535 AA.
AC   Q99518; Q5EBX4; Q86U73; Q9BRX1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   31-JUL-2019, sequence version 5.
DT   07-APR-2021, entry version 190.
DE   RecName: Full=Dimethylaniline monooxygenase [N-oxide-forming] 2;
DE            EC=1.14.13.8;
DE   AltName: Full=Dimethylaniline oxidase 2;
DE   AltName: Full=FMO 1B1;
DE   AltName: Full=Pulmonary flavin-containing monooxygenase 2;
DE            Short=FMO 2;
GN   Name=FMO2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE FMO2*2A), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, POLYMORPHISM, AND CHARACTERIZATION OF VARIANT
RP   472-GLN--SER-535 DEL.
RC   TISSUE=Lung;
RX   PubMed=9804831; DOI=10.1074/jbc.273.46.30599;
RA   Dolphin C.T., Beckett D.J., Janmohamed A., Cullingford T.E., Smith R.L.,
RA   Shephard E.A., Phillips I.R.;
RT   "The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of
RT   other primates, encodes a truncated, nonfunctional protein.";
RL   J. Biol. Chem. 273:30599-30607(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE FMO2*2A), AND VARIANTS GLY-36;
RP   TYR-69; SER-81; SER-182; LEU-195; GLN-238; GLY-314; THR-391 AND LYS-413.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE FMO2*2A).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE FMO2*1).
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE FMO2*2A).
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE FMO2*2A).
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND POLYMORPHISM.
RX   PubMed=11042094; DOI=10.1006/taap.2000.9050;
RA   Whetstine J.R., Yueh M.F., McCarver D.G., Williams D.E., Park C.S.,
RA   Kang J.H., Cha Y.N., Dolphin C.T., Shephard E.A., Phillips I.R.,
RA   Hines R.N.;
RT   "Ethnic differences in human flavin-containing monooxygenase 2 (FMO2)
RT   polymorphisms: detection of expressed protein in African-Americans.";
RL   Toxicol. Appl. Pharmacol. 168:216-224(2000).
RN   [8]
RP   SUMOYLATION AT LYS-492.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20388717; DOI=10.1074/jbc.m110.106955;
RA   Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,
RA   Eriksson J.E., Sistonen L.;
RT   "In vivo identification of sumoylation sites by a signature tag and
RT   cysteine-targeted affinity purification.";
RL   J. Biol. Chem. 285:19324-19329(2010).
RN   [9]
RP   VARIANTS GLY-36; ILE-59; SER-182; LEU-195; GLN-238; THR-391 AND LYS-413.
RX   PubMed=12527699; DOI=10.1124/dmd.31.2.187;
RA   Furnes B., Feng J., Sommer S.S., Schlenk D.;
RT   "Identification of novel variants of the flavin-containing monooxygenase
RT   gene family in African Americans.";
RL   Drug Metab. Dispos. 31:187-193(2003).
RN   [10]
RP   POLYMORPHISM.
RX   PubMed=18794725; DOI=10.1097/fpc.0b013e3283097311;
RA   Veeramah K.R., Thomas M.G., Weale M.E., Zeitlyn D., Tarekegn A., Bekele E.,
RA   Mendell N.R., Shephard E.A., Bradman N., Phillips I.R.;
RT   "The potentially deleterious functional variant flavin-containing
RT   monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.";
RL   Pharmacogenet. Genomics 18:877-886(2008).
CC   -!- FUNCTION: Catalyzes the N-oxidation of certain primary alkylamines to
CC       their oximes via an N-hydroxylamine intermediate. Inactive toward
CC       certain tertiary amines, such as imipramine or chloropromazine. Can
CC       catalyze the S-oxidation of methimazole. {ECO:0000269|PubMed:9804831}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + N,N-dimethylaniline + NADPH + O2 = H2O + N,N-
CC         dimethylaniline N-oxide + NADP(+); Xref=Rhea:RHEA:24468,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16269, ChEBI:CHEBI:17735, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; EC=1.14.13.8;
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane
CC       {ECO:0000250|UniProtKB:P17635}; Single-pass membrane protein
CC       {ECO:0000255}. Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P17635}; Single-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Expressed in lung (at protein level). Expressed
CC       predominantly in lung, and at a much lesser extent in kidney. Also
CC       expressed in fetal lung, but not in liver, kidney and brain.
CC       {ECO:0000269|PubMed:11042094, ECO:0000269|PubMed:9804831}.
CC   -!- POLYMORPHISM: The sequence shown is that of the allele FMO2*1. FMO2*2A
CC       is the major allele in the human population, however it encodes a
CC       truncated and catalytically inactive protein (PubMed:9804831). FMO2*2A
CC       occurs in essentially 100% of Caucasians and Asians (PubMed:9804831).
CC       FMO2*1 is present at a frequency of approximately 4% to 13% in the
CC       sample of population of African descent (PubMed:9804831,
CC       PubMed:11042094, PubMed:18794725). {ECO:0000269|PubMed:11042094,
CC       ECO:0000269|PubMed:18794725, ECO:0000269|PubMed:9804831}.
CC   -!- SIMILARITY: Belongs to the FMO family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fmo2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y09267; CAA70462.1; -; mRNA.
DR   EMBL; AY916056; AAW82431.1; -; Genomic_DNA.
DR   EMBL; BT006979; AAP35625.1; -; mRNA.
DR   EMBL; AL021026; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF459607; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471067; EAW90889.1; -; Genomic_DNA.
DR   EMBL; BC005894; AAH05894.1; -; mRNA.
DR   CCDS; CCDS1293.2; -.
DR   RefSeq; NP_001451.2; NM_001460.4.
DR   SMR; Q99518; -.
DR   BioGRID; 108614; 1.
DR   IntAct; Q99518; 4.
DR   STRING; 9606.ENSP00000209929; -.
DR   ChEMBL; CHEMBL3542432; -.
DR   iPTMnet; Q99518; -.
DR   PhosphoSitePlus; Q99518; -.
DR   BioMuta; FMO2; -.
DR   DMDM; 327478599; -.
DR   MassIVE; Q99518; -.
DR   PaxDb; Q99518; -.
DR   PeptideAtlas; Q99518; -.
DR   PRIDE; Q99518; -.
DR   ProteomicsDB; 78307; -.
DR   Antibodypedia; 34377; 141 antibodies.
DR   DNASU; 2327; -.
DR   Ensembl; ENST00000209929; ENSP00000209929; ENSG00000094963.
DR   GeneID; 2327; -.
DR   KEGG; hsa:2327; -.
DR   UCSC; uc057ngi.1; human.
DR   CTD; 2327; -.
DR   DisGeNET; 2327; -.
DR   GeneCards; FMO2; -.
DR   HGNC; HGNC:3770; FMO2.
DR   HPA; ENSG00000094963; Tissue enhanced (adipose tissue, esophagus, lung).
DR   MIM; 603955; gene.
DR   neXtProt; NX_Q99518; -.
DR   OpenTargets; ENSG00000094963; -.
DR   PharmGKB; PA164741534; -.
DR   VEuPathDB; HostDB:ENSG00000094963.13; -.
DR   eggNOG; KOG1399; Eukaryota.
DR   GeneTree; ENSGT00940000161099; -.
DR   HOGENOM; CLU_006909_8_2_1; -.
DR   InParanoid; Q99518; -.
DR   OMA; FMEWEHH; -.
DR   OrthoDB; 405736at2759; -.
DR   PhylomeDB; Q99518; -.
DR   TreeFam; TF105285; -.
DR   BRENDA; 1.14.13.8; 2681.
DR   PathwayCommons; Q99518; -.
DR   Reactome; R-HSA-217271; FMO oxidises nucleophiles.
DR   BioGRID-ORCS; 2327; 2 hits in 982 CRISPR screens.
DR   ChiTaRS; FMO2; human.
DR   GeneWiki; FMO2; -.
DR   GenomeRNAi; 2327; -.
DR   Pharos; Q99518; Tbio.
DR   PRO; PR:Q99518; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q99518; protein.
DR   Bgee; ENSG00000094963; Expressed in upper lobe of lung and 198 other tissues.
DR   ExpressionAtlas; Q99518; baseline and differential.
DR   Genevisible; Q99518; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0004499; F:N,N-dimethylaniline monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0017144; P:drug metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006739; P:NADP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0070995; P:NADPH oxidation; IDA:UniProtKB.
DR   GO; GO:0006082; P:organic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0072592; P:oxygen metabolic process; IEA:Ensembl.
DR   GO; GO:0009404; P:toxin metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:BHF-UCL.
DR   Gene3D; 3.50.50.60; -; 2.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   InterPro; IPR000960; Flavin_mOase.
DR   InterPro; IPR020946; Flavin_mOase-like.
DR   InterPro; IPR002254; Flavin_mOase_2.
DR   Pfam; PF00743; FMO-like; 1.
DR   PIRSF; PIRSF000332; FMO; 1.
DR   PRINTS; PR00370; FMOXYGENASE.
DR   PRINTS; PR01122; FMOXYGENASE2.
DR   SUPFAM; SSF51905; SSF51905; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Endoplasmic reticulum; FAD; Flavoprotein; Isopeptide bond;
KW   Magnesium; Membrane; Microsome; Monooxygenase; NADP; Oxidoreductase;
KW   Reference proteome; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P17635"
FT   CHAIN           2..535
FT                   /note="Dimethylaniline monooxygenase [N-oxide-forming] 2"
FT                   /id="PRO_0000147646"
FT   TRANSMEM        510..530
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   NP_BIND         9..13
FT                   /note="FAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   NP_BIND         40..41
FT                   /note="FAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   NP_BIND         60..61
FT                   /note="NADP"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   NP_BIND         61..62
FT                   /note="FAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   NP_BIND         195..198
FT                   /note="NADP"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   BINDING         32
FT                   /note="FAD"
FT                   /evidence="ECO:0000250|UniProtKB:Q9HFE4"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P17635"
FT   CROSSLNK        492
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:20388717"
FT   VARIANT         36
FT                   /note="D -> G (in dbSNP:rs2020870)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_014840"
FT   VARIANT         59
FT                   /note="V -> I (in dbSNP:rs55708639)"
FT                   /evidence="ECO:0000269|PubMed:12527699"
FT                   /id="VAR_015361"
FT   VARIANT         69
FT                   /note="F -> Y (in dbSNP:rs28745274)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022185"
FT   VARIANT         81
FT                   /note="F -> S (in dbSNP:rs2020860)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014841"
FT   VARIANT         182
FT                   /note="F -> S (in dbSNP:rs2307492)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_014842"
FT   VARIANT         195
FT                   /note="S -> L (in dbSNP:rs2020862)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_014843"
FT   VARIANT         238
FT                   /note="R -> Q (in dbSNP:rs28369895)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_015362"
FT   VARIANT         314
FT                   /note="E -> G (in dbSNP:rs2020863)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022186"
FT   VARIANT         391
FT                   /note="R -> T (in dbSNP:rs28369899)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_015363"
FT   VARIANT         413
FT                   /note="N -> K (in dbSNP:rs2020865)"
FT                   /evidence="ECO:0000269|PubMed:12527699, ECO:0000269|Ref.2"
FT                   /id="VAR_014844"
FT   VARIANT         472..535
FT                   /note="Missing (in allele FMO2*2A; loss of monooxygenase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9804831, ECO:0000269|Ref.2,
FT                   ECO:0000269|Ref.3, ECO:0000269|Ref.5"
FT                   /id="VAR_081836"
FT   CONFLICT        71
FT                   /note="D -> DD (in Ref. 2; AAW82431)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   535 AA;  60907 MW;  39A5587AC7BF50B8 CRC64;
     MAKKVAVIGA GVSGLISLKC CVDEGLEPTC FERTEDIGGV WRFKENVEDG RASIYQSVVT
     NTSKEMSCFS DFPMPEDFPN FLHNSKLLEY FRIFAKKFDL LKYIQFQTTV LSVRKCPDFS
     SSGQWKVVTQ SNGKEQSAVF DAVMVCSGHH ILPHIPLKSF PGMERFKGQY FHSRQYKHPD
     GFEGKRILVI GMGNSGSDIA VELSKNAAQV FISTRHGTWV MSRISEDGYP WDSVFHTRFR
     SMLRNVLPRT AVKWMIEQQM NRWFNHENYG LEPQNKYIMK EPVLNDDVPS RLLCGAIKVK
     STVKELTETS AIFEDGTVEE NIDVIIFATG YSFSFPFLED SLVKVENNMV SLYKYIFPAH
     LDKSTLACIG LIQPLGSIFP TAELQARWVT RVFKGLCSLP SERTMMMDII KRNEKRIDLF
     GESQSQTLQT NYVDYLDELA LEIGAKPDFC SLLFKDPKLA VRLYFGPCNS YQYRLVGPGQ
     WEGARNAIFT QKQRILKPLK TRALKDSSNF SVSFLLKILG LLAVVVAFFC QLQWS
//
